Royalty Pharma plc shareholders approved Authorization to allot shares without pre-emptive rights at the 2026-06-04 meeting.
“Proposal 10. To authorize the Board of Directors to allot shares without rights of pre-emption:”
Royalty Pharma plc — fact timeline
Source-grounded facts extracted from Royalty Pharma plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Royalty Pharma plc shareholders approved Authorization to allot shares at the 2026-06-04 meeting.
“Proposal 9. To authorize the Board of Directors to allot shares:”
Royalty Pharma plc shareholders approved Approval of share purchase agreements and counterparties at the 2026-06-04 meeting.
“Proposal 8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares:”
Royalty Pharma plc shareholders approved Authorization for Board to determine U.K. statutory auditor remuneration at the 2026-06-04 meeting.
“Proposal 7. To authorize the Board of Directors to determine the remuneration of the Company’s U.K. statutory auditor:”
Royalty Pharma plc shareholders approved Re-appointment of Ernst & Young as U.K. statutory auditor at the 2026-06-04 meeting.
“Proposal 6. To re-appoint Ernst & Young as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders:”
Royalty Pharma plc shareholders approved Advisory vote on U.K. directors' remuneration report at the 2026-06-04 meeting.
“Proposal 5. To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts:”
Royalty Pharma plc shareholders approved Approval of U.K. statutory accounts and reports at the 2026-06-04 meeting.
“Proposal 4. To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2025 ("U.K. Annual Report and Accounts") :”
Royalty Pharma plc shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-06-04 meeting.
“Proposal 3. To ratify the appointment of Ernst & Young LLP, as the Company’s independent registered public accounting firm:”
Royalty Pharma plc shareholders approved Advisory vote on executive compensation at the 2026-06-04 meeting.
“Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers:”
Royalty Pharma plc shareholders approved Election of nine directors at the 2026-06-04 meeting.
“Proposal 1. To elect nine directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2027 Annual General Meeting of Shareholders:”
Royalty Pharma plc entered into Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent and the other lenders valued at $1,800,000,000 revolving credit facility, maturing May 22, 2031, with interest rate options based on (effective 2026-05-22).
“On May 22, 2026, Royalty Pharma plc (the “Company”), Royalty Pharma Holdings Ltd, a non-wholly owned consolidated subsidiary of the Company (“RPH”), and Royalty Pharma Manager, LLC (“RPM”) entered into that certain Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent (the “Administrative Agent”) and the other lenders thereto (the “Credit Agreement”).”
Royalty Pharma plc incurred revolving credit of $1.8 billion with Bank of America, N.A., as Administrative Agent at base rate determined by reference to the highest of (1) the administrative agent maturing May 22, 2031.
“Credit Agreement were terminated in full. The Credit Agreement provides for an unsecured revolving credit facility (the “Revolving Credit Facility”) in an amount equal to $1.8 billion that is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal”
Royalty Pharma plc reported first quarter of 2026 results: revenue $925 million. Guidance raised.
“Press Release May 6, 2026 R oyalty Pharma reports first quarter 2026 results Portfolio Rece ipts growth o f 10% to $925 million ; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million”
Royalty Pharma plc: Amended and restated the articles of association of Royalty Pharma Holdings Ltd, adopted as of May 16, 2025, concurrently with the consummation of the Transaction (effective 2025-05-16).
“Concurrently with the consummation of the Transaction, pursuant to the terms of the Purchase Agreement, the articles of association of RPH were amended and restated in their entirety by a special resolution of the shareholders of RPH and written class consents of each of the holder of the class C ordinary share of RPH and the holder of the class D ordinary share of RPH, and were adopted as of May 16, 2025 (the "RPH A&R Articles of Association").”
Royalty Pharma plc: Amended and restated the articles of association of Royalty Pharma plc to provide additional rights to redesignate Class B ordinary shares into deferred shares and refine calling of general meetings and class consents (effective 2025-05-12).
“In connection with the Transaction, the articles of association of the Company were amended and restated in their entirety by a special resolution passed by the shareholders of the Company at the Annual General Meeting and Special Meeting of Shareholders held on May 12, 2025 and a written class consent of the holders of the Class B ordinary shares of the Company (the "Company A&R Articles of Association").”
Royalty Pharma plc completed an acquisition involving Sellers (of RP LLC) for $200,000,000 of cash, less the aggregate amount of management fee payments ... and 24,530,266 non-voting Class E ordinary shares of RPH (closed 2025-05-16).
“of RP LLC from the Sellers. Pursuant to the Purchase Agreement, the aggregate consideration paid to, or at the direction of, the Sellers in the Transaction consisted of (i) $200,000,000 of cash, less the aggregate amount of management fee payments in respect of calendar year 2025 made to and actually received by RP Management and RP LLC and their respective”
Vlad Coric was appointed as Director at Royalty Pharma plc.
“Effective April 7, 2025, Dr. Vlad Coric was appointed to serve as a new member of the Board of Directors (the “Board”) of Royalty Pharma plc (the “Company”).”
Royalty Pharma plc: Amended and restated articles of association of Royalty Pharma Holdings Limited in connection with a restructuring (effective 2024-12-31).
“On December 31, 2024, the articles of association of RP Holdings (the “Articles”) were amended and restated in their entirety in connection with the Restructuring.”
Royalty Pharma plc updated its first quarter of 2024 guidance (reaffirmed).
“On May 9, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Royalty Pharma plc updated its the fourth quarter and full year of 2023 guidance (initiated).
“On February 15, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
Royalty Pharma plc amended "Third Amendment" with Bank of America, N.A., as Administrative Agent and the other lenders thereto valued at increases the borrowing capacity under the Credit Agreement from $1.5 billion to $1.8 billion (effective 2023-12-22).
“On December 22, 2023, Royalty Pharma plc (the “Company”) and Royalty Pharma Holdings Ltd., a non-wholly owned consolidated subsidiary of the Company, entered into Amendment No. 3 (the “Third Amendment”) to the Amended and Restated Revolving Credit Agreement, dated as of September 15, 2021, as amended by Amendment No. 1 to Credit Agreement, dated as of October 31, 2022 and as further amended by Amendment No. 2 to Credit Agreement, dated as of May 16, 2023, with Bank of America, N.A., as Administrative Agent and the other lenders thereto (as so amended, the “Credit Agreement”).”
Royalty Pharma plc updated its the quarter ended September 30, 2023 guidance (raised).
“On November 8, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Royalty Pharma plc incurred revolving credit of $350 million with Royalty Pharma Holdings Ltd at not specified maturing five-year unsecured revolving credit facility.
“Royalty Pharma Holdings Ltd, a subsidiary of Royalty Pharma plc, borrowed $350 million under its existing five-year unsecured revolving credit facility (the "Revolving Credit Facility") to fund a portion of its previously announced purchase of additional royalties on Roche's Evrysdi ® (risdiplam) from PTC Therapeutics, Inc.”
Royalty Pharma plc updated its the quarter ended June 30, 2023 guidance (raised).
“Royalty Pharma plc issued a press release announcing its financial results for the quarter ended June 30, 2023”
Royalty Pharma plc shareholders approved To authorize the board of directors to determine the remuneration of the Company’s U.K. statutory auditor at the 2023-06-22 meeting.
“Proposal 7. To authorize the board of directors to determine the remuneration of the Company’s U.K. statutory auditor: For Against Abstain 534,177,160 97,715 76,422 There were no broker non-votes on this proposal.”
Royalty Pharma plc shareholders approved To re-appoint Ernst & Young Chartered Accountants as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders at the 2023-06-22 meeting.
“Proposal 6. To re-appoint Ernst & Young Chartered Accountants as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders: For Against Abstain 534,146,610 136,605 68,082 There were no broker non-votes on this proposal.”
Royalty Pharma plc shareholders approved To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts at the 2023-06-22 meeting.
“Proposal 5. To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts: For Against Abstain Broker Non-Votes 483,001,347 29,165,130 130,452 22,054,368”
Royalty Pharma plc shareholders approved To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2022 ("U.K. Annual Report and Acco at the 2023-06-22 meeting.
“Proposal 4. To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2022 (“U.K. Annual Report and Accounts”) : For Against Abstain 533,634,007 83,848 633,442 There were no broker non-votes on this proposal.”
Royalty Pharma plc shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm at the 2023-06-22 meeting.
“Proposal 3. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm: For Against Abstain 534,159,940 122,640 68,717 There were no broker non-votes on this proposal.”
Royalty Pharma plc shareholders approved To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers at the 2023-06-22 meeting.
“Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 483,910,458 28,152,706 233,765 22,054,368”
Royalty Pharma plc shareholders approved To elect ten directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2024 Annual General Meeting of Shareholders at the 2023-06-22 meeting.
“Proposal 1. To elect ten directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2024 Annual General Meeting of Shareholders: Nominee For Against Abstain Broker Non-Votes Pablo Legorreta 502,375,930 9,675,993 245,006 22,054,368 Henry Fernandez 436,729,886 75,363,229 203,814 22,054,368 Bonnie Bassler, Ph.D. 508,838,926 3,265,116 192,887 22,054,368 Errol De Souza, Ph.D. 473,005,611 39,098,656 192,662 22,054,368 Catherine Engelbert 446,746,829 65,346,788 203,312 22,054,368 M. Germano Giuliani 510,728,863 1,394,714 173,352 22,054,368 David Hodgson 499,416,709 12,686,655 193,565 22,054,368 Ted Love, M.D. 503,788,473 8,315,977 192,479 22,054,368 Gregory Norden 425,957,451 86,156,645 182,833 22,054,368 Rory Riggs 510,716,352 1,408,407 172,170 22,054,368”
Royalty Pharma plc updated its the quarter ended March 31, 2023 guidance (reaffirmed).
“On May 9, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Royalty Pharma plc: Amended Articles of Association to facilitate share repurchase program (effective 2023-03-24).
“On March 24, 2023, Royalty Pharma Holdings Ltd adopted amendments to its Articles of Association (the “RP Holdings Articles of Association”) to facilitate the share repurchase program that was announced by Royalty Pharma plc on March 27, 2023. The RP Holdings Articles of Association are filed herewith as Exhibit 3.2.”
Royalty Pharma plc updated its the quarter and year ended December 31, 2022 guidance (initiated).
“On February 15, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
Royalty Pharma plc announced a impairment with charges of $273.6 million affecting financial royalty asset associated with gantenerumab.
“endpoint of slowing clinical decline, which led the Company to conclude its financial royalty asset is impaired. The Company expects that the non-cash impairment charge will be $273.6 million, which was the net carrying value of the asset as of September 30, 2022. No portion of the impairment charge relates to future cash expenditures. SIGNATURES Pursuant to the”
Royalty Pharma plc updated its the third quarter of 2022 guidance (raised).
“On November 8, 2022, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.